EVALUATION OF THE SAFETY AND EFFICACY OF MEFLOQUINE AS INTERMITTENT PREVENTIVE TREATMENT FOR MALARIA IN PREGNANCY

Not Applicable

• Conditions: Malaria; Pregnancy and Childbirth

• Registration Number: PACTR2010020001429343
• Lead Sponsor: FCRB

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2009-05-27
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Other
• Sex: Female
• Target Recruitment: 0

Inclusion Criteria

Permanent resident in the area
Gestational age at the first antenatal visit < 28 weeks
Signed informed consent
Agreement to deliver in the study site's maternity wards

Exclusion Criteria

Residence outside the study area or planning to move out in the following 18 months from enrollment
Gestational age at the first antenatal visit > 28 weeks of pregnancy
Known history of allergy to sulfa drugs or mefloquine
Known history of severe renal, hepatic, psychiatric or neurological disease
MQ or halofantrine treatment in the preceding 4 weeks
HIV infection
Participating in other studies

Study & Design

• Study Type: Interventional
• Study Design: Not specified